Welcome to our dedicated page for Medirom Healthcare Technologies SEC filings (Ticker: MRM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MEDIROM Healthcare Technologies Inc. filings document a foreign private issuer that reports to the SEC on Form 6-K and annual reports under Form 20-F. The company’s disclosures cover its Japan-based wellness salon operations, digital preventive healthcare products, ADR/ADS voting materials, and current reports furnished for press releases and material corporate events.
MRM filings include ordinary general meeting notices and proxy cards for common share and American Depositary Share holders, convertible-type corporate bond issuances under Japanese law, loan and maturity-extension agreements, registration statement incorporation references, KPI reporting changes, and partnership updates for World ID, Orb authentication, MOTHER Bracelet and REMONY. These records also describe capital structure, governance procedures, financing terms, risk language and foreign-issuer reporting mechanics.
Medirom Healthcare Technologies Inc. director Ogawa Tomoya filed an initial ownership report showing he directly holds 28,500 Common Shares of the company. This filing is a baseline disclosure of his equity stake and does not reflect any new share purchases or sales.
Medirom Healthcare Technologies Inc. director Nojima Akira has reported initial beneficial ownership of 1,200 Common Shares. These shares are held directly, and the filing does not reflect any recent buy or sell activity, only the director’s current equity position in the company.
Medirom Healthcare Technologies Inc. filed an initial ownership report for Chief Financial Officer and director Fujiwara Fumitoshi. The filing shows direct beneficial ownership of 40,000 Common Shares following the reported position. This Form 3 does not reflect any new purchase or sale transactions, only the existing holdings.
Medirom Healthcare Technologies Inc. director and Chief Executive Officer Eguchi Kouji filed an initial ownership report showing his existing stake in the company. He directly holds 1,877,460 common shares, plus additional indirect holdings, and holds options to purchase 150,000 common shares and 36,500 common shares at stated exercise prices and terms.
Healthcare Technologies Inc. reported that its Master Service Agreement with Tools for Humanity and World Foundation became effective on February 2, 2026. The partnership is tied to deployment of Orbs biometric devices in Japan.
The company currently has Orbs at more than 150 locations, with cumulative authentications exceeding 20,000. Based on current performance, if it expands to about 3,000 locations nationwide in Japan, Healthcare Technologies estimates it could generate approximately USD 39 million (about JPY 6.10 billion) in income before income taxes over the next two years under the agreement, though this projection is forward-looking and subject to risks.
Healthcare Technologies Inc. has refinanced maturing debt with a mix of new convertible bonds and a secured loan to its main lender, Kufu Company Holdings Inc. The company issued fourth unsecured convertible corporate bonds totaling JPY 275,000,000 at 5.0% interest, maturing on June 30, 2026, with an option to extend to December 25, 2026. These bonds can be converted into common shares at JPY 330 per share during a defined exercise period, instead of being repaid in cash. Separately, JPY 200,000,000 of the earlier bonds were refinanced into a loan bearing 10.0% interest and due March 31, 2026, secured by a pledge over all shares of subsidiary MOTHER Labs Inc. The remaining JPY 25,000,000 of the original bonds was repaid in cash.
Healthcare Technologies Inc. reported updated key performance indicators for December 2025. Its salon operation business served 70,499 customers, with record-high sales per customer of JPY 7,926 per visit and a repeat customer ratio of 77.8%, above the Japanese industry average sales per customer of JPY 4,806.
The company will shift from monthly to quarterly KPI disclosures starting with the December 2025 release. It also highlighted a compensated World ID initiative launched with Tools for Humanity and Hakuhodo Inc. and, in its Lav® health tech business, contracts with 102 corporate insurance associations and 12,398 cumulative app users as of December 2025.
Healthcare Technologies Inc. filed a Form 6-K after entering a Master Service Agreement with Tools for Humanity and the World Foundation to support adoption of World ID in Japan. The company plans to deploy Orb authentication devices across approximately 3,000 locations nationwide, a major expansion from an initially planned 100 locations.
Within its existing operations, Orbs are already installed at more than 150 Re.Ra.Ku wellness centres, with a goal of reaching about 300 centres across the Re.Ra.Ku Group. Beyond company-operated sites, Healthcare Technologies is negotiating with 370 third-party locations and intends to use a standard framework for contracts, branding, privacy protection, and quality control so authentication services are delivered consistently across partner locations.
MEDIROM Healthcare Technologies Inc. reported operational progress in its collaboration with World, a Proof of Human authentication protocol co-founded by Sam Altman and Alex Blania. The company announced that cumulative Proof of Human authentications using the World ID device “Orb” at its Re.Ra.Ku-centered stores in Japan surpassed 20,000 as of December 28, 2025, roughly doubling from 10,000 in about two months. This growth was largely driven by MEDIROM’s 25th anniversary “5-Minute Shoulder Massage Campaign for 250,000 People,” which paired free massage experiences with on-site human verification. MEDIROM plans to continue rolling out Orb devices to 200 salons nationwide, aiming to broaden access to this digital identity infrastructure while leveraging its existing wellness salon network.
MEDIROM Healthcare Technologies Inc. closed its previously announced sale and issuance of an aggregate principal amount of JPY400,000,000 of its Third Unsecured Convertible-Type Corporate Bonds with Share Options to 11 investors on December 12, 2025. Net proceeds are approximately JPY400,000,000, which the company plans to use for general corporate or financing purposes it deems appropriate from time to time.
The bonds were issued and sold outside the United States in reliance on Regulation S under the Securities Act of 1933. The bonds, the common shares issuable upon conversion, and any American Depositary Shares representing those shares have not been registered under U.S. securities laws and may not be offered or sold in the United States without registration or an applicable exemption. The company includes forward-looking statement cautions and incorporates this report by reference into its registration statements on Form S-8 and Form F-3.